Pharmaceutical Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X

Most Read

  1. Researchers uncover pathogenic mechanism causing IPF
  2. Study shows methylphenidate is most effective ADHD drug for under-16s
  3. The next generation of antimalarials
  4. Researchers claim to have uncovered how thalidomide caused birth defects
  5. Medicines for Malaria Venture: steps towards eliminating a global scourge

Latest Content

Gerresheimer at Medtec China

Gerresheimer develops and produces innovative drug delivery systems and medical and diagnostic products for prestigious international customers.

Mustang Bio licenses gene therapy for bubble boy disease

US-based biopharmaceutical firm Mustang Bio has entered an exclusive worldwide licence agreement with St. Jude Children’s Research Hospital for a new gene therapy to treat X-linked severe combined immunodeficiency (X-SCID or bubble boy disease).

Shire submits NDA in Japan for Intuniv to treat ADHD

Irish biotechnology company Shire, through its partner Shionogi, has filed a new drug application (NDA) in Japan seeking approval to manufacture and market its Intuniv medicine for the treatment of adults with attention deficit hyperactivity disorder (ADHD).

Latest News

Read our magazine

Pharma Technology Focus is the essential reading material for decision-makers in the pharmaceutical industry, bringing you the latest news and analysis in an exciting, interactive format.

Send me notifications of new editions:

Go Top